SPONSOR
Dizal Pharmaceuticals
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2, Phase 1
Dizal Pharmaceuticals is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including T-cell Lymphomas, Lymphoma, Non-Hodgkin, Advanced Solid Tumors.
The trial portfolio spans Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Dizal Pharmaceuticals
How many clinical trials has Dizal Pharmaceuticals sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Dizal Pharmaceuticals, of which 3 are actively recruiting participants. These trials cover conditions including T-cell Lymphomas, Lymphoma, Non-Hodgkin, Advanced Solid Tumors. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Dizal Pharmaceuticals research focus on?
Dizal Pharmaceuticals clinical trials span T-cell Lymphomas, Lymphoma, Non-Hodgkin, Advanced Solid Tumors. The research pipeline includes Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Dizal Pharmaceuticals clinical trial?
To participate in a Dizal Pharmaceuticals trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Dizal Pharmaceuticals trials with current recruitment status updated daily.
Clinical Trials by Dizal Pharmaceuticals
NCT07496229 Phase 1, Phase 2
Recruiting
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
T-cell Lymphomas
NCT05824585 Phase 1
Recruiting
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
NCT07328217 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology